ODAIA
AI company delivering predictive commercial intelligence for pharma.
The record
- Vertical
- Pharma Commercial Intelligence
- Headquarters
- Boston (November 17, 2026 release dateline)
- Founded
- 2018
- Stage
- Series C
What they do
ODAIA is an AI company delivering predictive commercial intelligence for pharma. A University of Toronto spinout founded in 2018, it predicts patient journeys, uncovers missed prescription opportunities and prioritizes healthcare professionals and channels. Its platform includes Brand Strategy Studio, Field Intelligence and Marketing Intelligence. Philip Poulidis is CEO and co-founder. The November 17, 2026 financing release is datelined Boston.
Leadership & founders
- Philip Poulidis
CEO and co-founder
Investors
- Monograph Capital
- PHM (part of Publicis Groupe)
- BDC Capital
- Flint Capital
- Innospark Ventures
- Graphite Ventures
- Threshold Ventures
- Wittington Ventures
History and progression
How ODAIA got here, step by step.
2018
University of Toronto spinout founded
ODAIA was founded in 2018 as a University of Toronto spinout.
17 November 2026
US$15 million Series C and PHM agreement
ODAIA closed a US$15 million Series C led by Monograph Capital and anchored by strategic investor PHM, part of Publicis Groupe. Returning investors were BDC Capital, Flint Capital, Innospark Ventures, Graphite Ventures, Threshold Ventures and Wittington Ventures. ODAIA also signed a Platform Agreement making PHM its exclusive U.S. agency partner. The release quotes Monograph partner Charles Conn.
Key products
- Brand Strategy Studio
- Module in ODAIA's predictive commercial intelligence platform.
- Field Intelligence
- Module in ODAIA's predictive commercial intelligence platform.
- Marketing Intelligence
- Module in ODAIA's predictive commercial intelligence platform.
Recent news
Related companies
Your daily HealthTech Signal
No hype. Just signal.
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: